Privia Health stock weighs 21.4 percent Q2 growth against slower guidance

Published on 10/07/2026 at 03:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Privia Health stock was last at USD 20.28 on October 6, 2026, while analysts set a USD 31.00 consensus target. Q2 EBITDA rose 29 percent.

PRVA, US74276R1023, Illustration mit AI erstellt.

Privia Health Group stock (ISIN US74276R1023) was last at USD 20.28 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, down 0.83 percent from the prior close. The investment case now turns on whether rapid Q2 expansion can offset a slower second-half growth profile.

Q2 growth remains substantial

According to Yahoo Finance, Privia reported Q2 2026 practice collections of USD 970 million, an increase of 12.4 percent from the prior-year quarter. Adjusted EBITDA rose 29 percent to USD 37.4 million, equal to 28.3 percent of care margin.

The operating base also expanded. Implemented providers reached 5,644 on June 30, 2026, up 10.1 percent year over year, while value-based attributed lives increased 19.2 percent. For the first half of 2026, practice collections rose 13.4 percent to USD 1.88 billion and adjusted EBITDA grew 32.5 percent to USD 74.1 million, according to Yahoo Finance.

Guidance meets a tougher comparison

Management raised its 2026 outlook across practice collections, care margin, platform contribution and EBITDA during the August 6, 2026 earnings call. The call also described a potential second-half deceleration in practice collections growth to 3 percent from 13 percent in the first half, reflecting a more conservative guidance posture.

The margin picture provides a counterweight. Adjusted EBITDA represented 28.3 percent of care margin in Q2, while management targets a long-term range of 30 percent to 35 percent. Privia also reported USD 412 million in cash and no debt at June 30, 2026, according to Benzinga.

Consensus stays above the quote

MarketBeat reports a Moderate Buy consensus from 14 analysts, with 11 Buy ratings and three Holds. The average 12-month target is USD 31.00, placing the target 52.8 percent above the October 6 price of USD 20.28.

Stock remains near yearly low

PRVA was last at USD 20.28 on Nasdaq on October 6, 2026, with a session range of USD 20.26 to USD 20.88. Its 52-week range was USD 18.91 to USD 28.82, leaving the stock 7.2 percent above the yearly low and 29.6 percent below the yearly high.